EPG Online Twitter 
EPG Online Blog 
Disease Knowledge Drug Updates
- Fostair 100/6 inhalation solution
- Epanutin capsules 25, 50 and 100mg
- Eprex 2000, 4000 and 10000 IU/ml solution for injection in pre-filled syringe
- FemSeven Conti
- Epanutin 300mg hard capsules
- Bedranol 80mg SR Capsules
- Bedranol 160mg SR Capsules
- Betim 10mg Tablets
- Carbo-Dome Cream
- Bisoprolol 2.5mg/5mg/10mg film coated tablet
- Phenergan Injection
- Rivotril 0.5 mg and 2 mgTablets
- Rivotril Ampoules
- RELPAX 20mg and 40mg Film-Coated Tablets
- Witch Doctor ® 81.5%w/w Gel
- Levetiracetam Actavis 1,000 mg film-coated tablets
- Levetiracetam Actavis 250 mg film-coated tablets
- Levetiracetam Actavis 500 mg film-coated tablets
- Levetiracetam Actavis 750 mg film-coated tablets
- Lidocaine Hydrochloride Injection BP 1% w/v plastic ampoules
- Lidocaine Hydrochloride Injection BP 2.0% w/v
- Omeprazole 10mg Capsules
- Omeprazole 20mg Capsules
- Panadol Extra Advance 500 mg/65 mg Tablets
- Allopurinol Tablets BP 300mg
- Allopurinol Tablets BP 100mg
- Anadin Ultra Double Strength 400mg Capsules/Anadin LiquiFast 400mg Capsules
- Calcipotriol Scalp Solution
- Bupivacaine Hydrochloride Injection BP 0.5% w/v.
- Lescol (fluvastatin* sodium) 20 mg and 40 mg capsules
- Meropenem 1 g Powder for Solution for Injection or Infusion
- VALTREX Tablets 250mg
- Vesicare 5mg & 10mg film-coated tablets
- Zomig 5mg Nasal Spray
- Water for Injections
- Tizanidine 2mg Tablets
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Orfadin 10 mg hard capsules
- Orfadin 2 mg hard capsules
- Natecal D3 Chewable Tablets
Osteoporosis
Please note - This EPG Osteoporosis affiliate search is for Doctors and other Healthcare Professionals.
Osteoporosis is a significant international health problem, affecting an estimated 200 million people worldwide;1 the majority of these cases involve women with postmenopausal osteoporosis (PMO).2 Approximately 1 out of every 3 women over the age of 50 will experience an osteoporotic fracture during their lifetime.
As the mean age of the population increases, the burden of osteoporosis will continue to escalate for both men and women. By 2050, the worldwide incidence of hip fracture is projected to increase by 310% in men and 240% in women,2 which, if left untreated, will result in an increase in all-cause mortality.3
Healthcare professionals are faced with a huge challenge of diagnosing, assessing severity and risk and selecting and monitoring treatment. EPGOnline together with our Osteoporosis partner Novartis Pharma AG aim to assist in improving patient care, and increase awareness amongst physicians and patients, of this condition.
References:
1. NIH Consensus Development Panel on Osteoporosis Prevention DaT. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285(6):785-795.
2. Albrand G, Munoz F, Sornay-Rendu E, Duboeuf F, Delmas PD. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 2003; 32(1):78-85.
3. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285(3):320-323.
- FOSAMAX Tablets
... is indicated for the treatment of osteoporosis in post-menopausal women to prevent fractures. 'Fosamax' is indicated for the treatment of osteoporosis in men to prevent fractures. 'Fosamax' is indicated for the treatment of glucocorticoid-induced osteoporosis and prevention of bone loss in post ... - ACTONEL 5 mg Film-coated Tablets
Treatment of postmenopausal osteoporosis, to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis, to reduce the risk of hip fractures. Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. To maintain or increase bone mass in ... - ACLASTA 5 mg
... Aclasta' is indicated for the treatment of osteoporosis in post-menopausal women and osteoporosis treatment in men both at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy ... - DIDRONEL PMO
Treatment of osteoporosis, and prevention of bone loss in postmenopausal women considered at risk of developing osteoporosis. Didronel PMO is particularly indicated in patients who are unable or unwilling to take oestrogen replacement therapy. Didronel PMO is also indicated for the prevention and ... - ACTONEL Once a Week
Treatment of postmenopausal osteoporosis , to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis, to reduce the risk of hip fractures. Treatment of osteoporosis in men at high risk of fractures - ESTRADOT Transdermal Patch
... symptoms in postmenopausal women. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis (for Estradot 50, 75 and 100 only). The experience of treating ...
